Coherus Oncology, Inc. Common Stock (CHRS) is a publicly traded Healthcare sector company. As of May 21, 2026, CHRS trades at $1.52 with a market cap of $229.83M and a P/E ratio of 0.92. CHRS moved +2.36% today. Year to date, CHRS is +4.86%; over the trailing twelve months it is +85.03%. Its 52-week range spans $0.66 to $2.62. Analyst consensus is strong buy with an average price target of $8.25. Rallies surfaces CHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes CHRS SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $1.52 |
| Market Cap | $229.83M |
| P/E Ratio | 0.92 |
| EPS | $1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.62 |
| 52-Week Low | $0.66 |
| Volume | 4.07K |
| Avg Volume | 0 |
| Revenue (TTM) | $46.88M |
| Net Income | $186.27M |
| Gross Margin | 68.06% |
5 analysts cover CHRS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.25.